There is inadequate quality oversight to assure that the Shringrix and Measles drug substances have the identity, strength, quality, and purity they purport or are represented to possess.
Inspection Record
GSK Vaccines GmbH — FDA 483 Findings
Inspectors Massoud MotamedThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and docs not adequately identify, document, or investigate the impact to drug substances.
Critical utilitiesr (b) (4) utilized as productL(b) (4) in the manufacture of Shingrix are not adequately qualified or routinely monitored to ensure reproducible quality.
Quality oversigflt and integrity of electronic data captured to support the manufacturing equipment, environmental monitoring, and manufacturing systems ( e.g., Process Control System) has not been established.
There is a lack of data to demonstrate the quality of'Ǖhe (b) (4) J prior to use for vaccine production.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.